Physician profile
Paul E Sheffield
NPI 1093783672
$1,427.89
in general payments reported to CMS, 2019-2025
23 companies · $27.39 in 2025
The $27.39 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $110 · 2020: $378 · 2021: $446 · 2022: $404 · 2023: $37.71 · 2024: $24.48 · 2025: $27.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $89.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $89.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $186.07 | 2020-2022 | |
| Abbvie INC. | $182.58 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.44 | 2019-2021 | |
| Novo Nordisk INC | $118.16 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.92 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $85.27 | 2021-2022 | |
| Amgen INC. | $83.30 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $79.61 | 2020-2021 | |
| Astellas Pharma US INC | $79.06 | 2019-2021 | |
| Lilly USA, LLC | $70.07 | 2020-2021 | |
| Allergan, INC. | $53.33 | 2019-2020 | |
| Glaxosmithkline, LLC. | $48.77 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $35.20 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.13 | 2021-2022 | |
| Shield Therapeutics INC | $27.39 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $24.48 | 2024 | |
| Dexcom, INC. | $20.95 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $16.76 | 2023 | |
| Abbott Laboratories | $16.05 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.36 | 2021 | |
| Evoke Pharma, INC. | $14.06 | 2020 | |
| Snap Diagnostics LLC | $13.05 | 2019 | |
| Esperion Therapeutics, INC. | $12.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Sheffield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.